Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03642964 · ClinicalTrials.gov registry record · Phase 2
A Study in Patients With Major Depressive Disorder
A Phase 2 study of Major Depressive Disorder (MDD), sponsored by Chase Therapeutics Corporation.
- Active
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT03642964 is a Phase 2 study of Major Depressive Disorder (MDD) that is active but no longer recruiting, run by Chase Therapeutics Corporation. The registered enrollment target is 24 participants, below the 157-participant average among 22 other Major Depressive Disorder (MDD) trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03642964, a Phase 2 study of Major Depressive Disorder (MDD), is active but no longer recruiting, sponsored by Chase Therapeutics Corporation.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a Phase 2a, placebo-controlled, single-blind study in up to 24 patients with major depressive disorder (MDD).
Conditions Studied
Interventions
- DRUG CTC-501
Study Locations (1)
California
- Collaborative Neuroscience Network - Long Beach
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2018-09-10 |
| Est. Completion | 2025-12-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03642964
The ClinicalTrials.gov registry entry for NCT03642964 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 157-participant average among 22 other Major Depressive Disorder (MDD) trials with a reported enrollment target (85% lower). The listed sponsor is Chase Therapeutics Corporation, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Major Depressive Disorder (MDD) appearing as the primary indexed condition, and to 1 intervention - of which CTC-501 is the first listed.
NCT03642964 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT03642964 about?
NCT03642964 is a clinical study titled "A Study in Patients With Major Depressive Disorder". This is a Phase 2a, placebo-controlled, single-blind study in up to 24 patients with major depressive disorder (MDD).
What is the current status of trial NCT03642964?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2018-09-10. Estimated completion is 2025-12-30.
What conditions does trial NCT03642964 study?
This clinical trial studies the following conditions: Major Depressive Disorder (MDD).
What interventions are being tested in trial NCT03642964?
The interventions under investigation include: CTC-501 (DRUG).
Who is sponsoring clinical trial NCT03642964?
This trial is sponsored by Chase Therapeutics Corporation, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03642964 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Major Depressive Disorder (MDD)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response
RECRUITING · Phase 2
-
A Study to Evaluate the Effectiveness of DT-101 in Patients With Depression
RECRUITING · Phase 2
-
Orexin Antagonism for Suicide Risk: A Proof-of-Concept Clinical Trial
RECRUITING · Phase 2
-
A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)
RECRUITING · Phase 2
-
Study to Evaluate Efficacy and Safety of Ropanicant in MDD Patients
ACTIVE NOT RECRUITING · Phase 2
-
Improving Depression Outcome by Enhancing Memory for Cognitive Therapy
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.